A bi-specific CAR-T cell therapy targeting CD19 and CD22 in relapsed or refractory B-ALL
Authors:
Open Access
- 28 July 2025
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-13
Abstract
CAR-T therapies targeting either CD19 or CD22 have shown significant promise for treating relapsed or refractory B-lineage acute lymphoblastic leukemia (r/r B-ALL). However, a common limitation is the high frequency of antigen loss, which leads to r/r B-ALL progression. To overcome progression caused by antigen loss, bi-specific CAR-T immunotherapies targeting both CD19 and CD22 may offer enhanced efficacy in eliminating r/r B-ALL and preventing relapse by hindering leukemia cell proliferation. In this study, we present both pre-clinical and clinical findings from an ongoing trial (NCT04303520) assessing the therapeutic efficacy of the CD19-CD22 bi-specific CAR-T therapy for r/r B-ALL patients. Pre-clinical data from animal models reveal that CD19-CD22 CAR-T cells effectively induce cytotoxicity, thus suppressing B-ALL cell proliferation. Notably, this dual-targeted approach outperforms single-target CAR-T treatments. From the Phase I trial encompassing 35 participants, 37.1% (13 out of 35 patients) experienced cytokine release syndrome, with only a single case of Grade III severity. Importantly, no neurotoxicity episodes were recorded post CD19-CD22 CAR-T administration. Common adverse events included hematological, gastrointestinal, and nutrition-related disturbances. B-ALL patients undergoing stem cell transplantation in tandem with CAR-T therapy exhibited a pronounced improvement in overall survival compared to those treated solely with CAR-T. The median overall survival duration was 21.49 ± 4.4 months (95% CI: 14.31–31.40 months), meanwhile one-year PFS and OS are 0.37 (95% CI, 0.21–0.49) and 0.62 (95% CI: 0.52–0.71), respectively. Clinical monitoring did not identify significant side effects associated with the CD19-CD22 regimen. To monitor the inflammation-associated factors accompanying CAR-T therapy, the peak value of CAR DNA copies was reached around Day 10, accompanied by a similar trend in the levels of inflammatory factors, including IFN- γ , Granzyme B, IL-6, and CRP. Collectively, our data advocate for the potential role of bi-specific CD19-CD22 CAR-T therapy in addressing r/r B-ALL. Trial registration number ClinicalTrials.gov (No. NCT04303520).Keywords
Funding Information
- Natural Science Foundation of Henan Province of China (222300420487, 222300420487, 222300420487)
- the scientific and technological project in Henan Province of China (222102310353, 222102310353, 222102310353)
- Government-funded Project on Traditional Chinese Medicine in Henan Province of China (2024ZY1010, 2024ZY1010, 2024ZY1010)
This publication has 40 references indexed in Scilit:
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJournal of Clinical Oncology, 2017
- Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Pediatric Blood & Cancer, 2015
- Characterization of CD22 expression in acute lymphoblastic leukemiaPediatric Blood & Cancer, 2015
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaCancer, 2013
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeukemia & Lymphoma, 2011
- Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialThe Lancet, 2010
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy, 2009
- Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cellsCancer Immunology, Immunotherapy, 2008
- Retroviral Vectors for High-Level Transgene Expression in T LymphocytesHuman Gene Therapy, 2003